US 12,168,654 B2
Pyrimidine derivative containing one deuterium atom and preparation process and use thereof
Xingshu Li, Guangdong (CN); Xinzi Chen, Guangdong (CN); Wei Yang, Guangdong (CN); and Jianmin Guo, Guangdong (CN)
Assigned to Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangdong (CN); and Guangdong CS-Lewwin Drug Research Co., Ltd., Guangdong (CN)
Filed by Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangdong (CN); and Guangdong CS-Lewwin Drug Research Co., Ltd., Guangdong (CN)
Filed on Jan. 25, 2021, as Appl. No. 17/156,794.
Application 17/156,794 is a continuation of application No. PCT/CN2019/105043, filed on Sep. 10, 2019.
Claims priority of application No. 201811059596.7 (CN), filed on Sep. 12, 2018; and application No. 201811623543.3 (CN), filed on Dec. 28, 2018.
Prior Publication US 2021/0139464 A1, May 13, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 403/10 (2006.01); A61K 31/4545 (2006.01); A61P 35/00 (2006.01); C07B 59/00 (2006.01); C07D 239/30 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/14 (2006.01)
CPC C07D 403/10 (2013.01) [A61P 35/00 (2018.01); C07B 59/002 (2013.01); C07D 239/30 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/14 (2013.01); C07B 2200/05 (2013.01)] 13 Claims
 
1. A pyrimidine derivative of Formula 2, a pharmaceutically acceptable salt thereof, or a pharmaceutical solvate thereof:

OG Complex Work Unit Chemistry
wherein X1 is CH; X2 is N; Y is deuterium; R1 is an alkyl containing one carbon; Z is oxygen; R2 is 4-piperidyl with the nitrogen atom attached to an alkyl containing one carbon; and each of R3-R8 is hydrogen.